Nicholas Investment Partners LP Buys 123,891 Shares of Xenon Pharmaceuticals Inc. $XENE

Nicholas Investment Partners LP boosted its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 104.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 242,989 shares of the biopharmaceutical company’s stock after purchasing an additional 123,891 shares during the period. Nicholas Investment Partners LP owned about 0.31% of Xenon Pharmaceuticals worth $10,891,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its position in Xenon Pharmaceuticals by 11.3% in the third quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company’s stock worth $56,171,000 after acquiring an additional 142,452 shares during the period. Neo Ivy Capital Management bought a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter valued at $2,001,000. HighVista Strategies LLC raised its position in shares of Xenon Pharmaceuticals by 80.2% during the 3rd quarter. HighVista Strategies LLC now owns 82,190 shares of the biopharmaceutical company’s stock valued at $3,300,000 after purchasing an additional 36,570 shares during the period. Assenagon Asset Management S.A. bought a new stake in shares of Xenon Pharmaceuticals during the 4th quarter valued at $5,342,000. Finally, Peregrine Capital Management LLC bought a new stake in shares of Xenon Pharmaceuticals during the 4th quarter valued at $7,837,000. Institutional investors own 95.45% of the company’s stock.

Insider Transactions at Xenon Pharmaceuticals

In related news, Director Gary Patou sold 1,322 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $70,251.08. Following the completion of the sale, the director owned 24,896 shares in the company, valued at $1,322,973.44. This trade represents a 5.04% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Gillian Cannon sold 1,190 shares of Xenon Pharmaceuticals stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the sale, the director owned 1,455 shares of the company’s stock, valued at $77,318.70. The trade was a 44.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 4.07% of the company’s stock.

Xenon Pharmaceuticals Price Performance

Shares of XENE opened at $52.10 on Friday. Xenon Pharmaceuticals Inc. has a 1-year low of $30.00 and a 1-year high of $63.95. The company has a 50-day moving average of $55.41 and a 200 day moving average of $48.95. The firm has a market capitalization of $5.04 billion, a price-to-earnings ratio of -11.09 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, meeting analysts’ consensus estimates of ($1.17). During the same quarter in the prior year, the business posted ($0.83) EPS. On average, equities analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on XENE. Weiss Ratings restated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Wednesday, April 8th. Bank of America restated a “buy” rating on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Jefferies Financial Group set a $100.00 price objective on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Needham & Company LLC dropped their price objective on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Finally, Royal Bank Of Canada lifted their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $77.20.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.